BioClinica Announces Record eClinical Growth in 2014
─ New Customers and Enhanced Product Offerings Increase Sales by 51 Percent ─
NEWTOWN, Pennsylvania, Feb. 4, 2015 /PRNewswire/ -- BioClinica®, Inc., a specialty clinical trials services and technology provider, today announced that 2014 was a record year for its eClinical technologies business unit, with sales soaring 51 percent above the previous year. BioClinica's continuing growth is on trend with industry analysts' projections that the eClinical market will reach $6.5 billion by 2020.
Logo - http://photos.prnewswire.com/prnh/20130403/PH87647LOGO
Contracts inked with 25 new clients in 2014 expands BioClinica's eClinical base to more than 150 active customers. Forty percent of these organizations chose multiple BioClinica products to maximize efficiencies in their clinical trials.
"In addition to first-time clients, many existing customers expanded their use to multiple products," said John Hubbard, CEO of BioClinica. "As the pharma and biotech industry retire outdated legacy systems, they are being replaced with BioClinica's superior alternatives which will serve them well into the future."
BioClinica's customer-centric focus and robust product lineup resulted in a sharp increase in multi-year, multi-million dollar licensing deals where companies are standardizing on BioClinica, including its Express Electronic Data Capture (EDC) solution. These agreements allow for unlimited use of Express EDC for significant efficiencies and costs-savings in the clinical trial process.
Last year BioClinica introduced several important technology advances including Compass, the "Intelligent Monitoring" solution. Compass enables sponsors to put under-utilized clinical data to work and realize tangible benefits from risk-based monitoring. Compass is being adopted by several clients to help raise overall clinical trial quality while lowering risks and monitoring costs. Compass co-developer Trevor McCaw will speak on the topic Risk-Based Monitoring Enabling Technology: Analytics with Action at the upcoming SCOPE Summit for Clinical Operations Executives.
Also in 2014, BioClinica entered into a technology transfer arrangement for Trident Interactive Response Technology (IRT) with a top ten pharma company. Trident provides patient randomization and drug dispensation and it empowers clinical trial sponsors to configure their own studies in a rapid manner. This technology was also the preferred IRT solution for several organizations within BioClinica's CRO Partner Program.
Another milestone in 2014 was the expansion of BioClinica's Optimizer clinical supply forecasting and management tool into the Optimizer Enterprise Suite, broadening use for organizations of any size interested in optimizing their supply chains. BioClinica penned new enterprise agreements for the product with three top life sciences companies in the fourth quarter alone.
To request a meeting with BioClinica to learn more about its eClinical Solutions or to schedule a product demonstration, call the hotline at 1-888-392-7456, email sales@bioclinica.com or complete the online Contact Us form. Follow BioClinica on the Trial Blazers blog at http://www.bioclinica.com/blog, and on Twitter at http://twitter.com/bioclinica.
About BioClinica, Inc.
BioClinica is a specialty clinical trials services provider that improves the development of new medical therapies by delivering expertise and technologies that enhance clinical research data and analytics, worldwide. The company offers industry-leading medical imaging services, enterprise eClinical technologies, clinical research centers and cardiovascular safety solutions that bring quality and efficiency to every phase of clinical development. BioClinica's experience spans three decades and includes thousands of studies in all therapeutic areas. The company serves more than 400 pharmaceutical, biotechnology, and device organizations – including all of the top 20 – through a network of offices in the U.S., Europe and Asia. For more information, please visit www.bioclinica.com.
Share this article